2,211 IQVIA Holdings Inc. $IQV Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 73,276 shares of the medical research company’s stock after selling 2,211 shares during the quarter. Fifth Third Bancorp’s holdings in IQVIA were worth $19,700,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Compass Financial Management LLC increased its position in IQVIA by 31.9% during the 3rd quarter. Compass Financial Management LLC now owns 157 shares of the medical research company’s stock worth $42,000 after purchasing an additional 38 shares in the last quarter. North Dakota State Investment Board lifted its holdings in IQVIA by 0.8% in the 3rd quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company’s stock valued at $1,361,000 after purchasing an additional 40 shares in the last quarter. Boston Trust Walden Corp lifted its holdings in IQVIA by 1.9% in the 3rd quarter. Boston Trust Walden Corp now owns 2,650 shares of the medical research company’s stock valued at $712,000 after purchasing an additional 50 shares in the last quarter. Apella Capital LLC lifted its holdings in IQVIA by 4.7% in the 3rd quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock valued at $319,000 after purchasing an additional 55 shares in the last quarter. Finally, Brighton Jones LLC boosted its stake in shares of IQVIA by 0.7% during the 3rd quarter. Brighton Jones LLC now owns 8,151 shares of the medical research company’s stock worth $2,191,000 after purchasing an additional 58 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the subject of a number of recent research reports. William Blair upgraded shares of IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. Rothschild & Co Redburn upped their price objective on shares of IQVIA from $284.00 to $287.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Stifel Nicolaus raised their target price on shares of IQVIA from $276.00 to $303.00 and gave the stock a “buy” rating in a research report on Wednesday, October 14th. JPMorgan Chase & Co. lifted their target price on shares of IQVIA from $295.00 to $325.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 28th. Finally, Morgan Stanley boosted their price target on IQVIA from $240.00 to $270.00 and gave the company an “equal weight” rating in a report on Thursday, September 17th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $294.21.

IQVIA Trading Down 2.1%

Shares of IQV stock opened at $265.44 on Friday. The firm’s 50-day simple moving average is $267.55 and its 200-day simple moving average is $211.88. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.83 and a quick ratio of 0.83. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $284.50. The firm has a market cap of $43.74 billion, a P/E ratio of 32.25, a PEG ratio of 2.41 and a beta of 1.16.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.05% and a return on equity of 30.02%. The firm had revenue of $4.43 billion during the quarter, compared to the consensus estimate of $4.37 billion. During the same period in the previous year, the firm earned $3.00 earnings per share. IQVIA’s revenue was up 8.0% compared to the same quarter last year. As a group, equities analysts forecast that IQVIA Holdings Inc. will post 11.53 EPS for the current year.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,446 shares of the company’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the completion of the sale, the insider directly owned 24,989 shares in the company, valued at $6,967,682.87. This represents a 15.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider James G. Berkshire sold 2,668 shares of the stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares in the company, valued at $2,845,883.70. This trade represents a 19.68% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.70% of the stock is owned by insiders.

About IQVIA

IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company’s offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.